Catalyst Biosciences Inc expected to post a loss of 24  cents a share - Earnings Preview

Gyre Therapeutics

12/08/2022 22:23

* Catalyst Biosciences Inc  CBIO.OQ   CBIO.O  is expected
to show
a fall in quarterly revenue when it reports  results on August
15 (estimated). 
    * ​Refinitiv's mean analyst estimate for Catalyst
Biosciences Inc
is for a loss of 24 cents per share. For the same quarter last
year, the company reported a loss of 64 cents per share.
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Catalyst
Biosciences Inc is $16​, above​ its last closing price of $1.86.
​​​

This summary was machine generated August 12 at 21:23 GMT.  All
figures in US dollars  unless otherwise stated